Gene Therapy Nearly Eliminates Hemophilia B Bleeding Episodes, Trial Shows

A hemophilia gene therapy developed by Spark Therapeutics and Pfizer nearly eliminated bleeding episodes in 10 patients who took part in a Phase 1/2 trial. The treatment, SPK-9001, worked so well in eight of the 10 that they were able to stop taking clotting factor replacements. Researchers published the preliminary trial findings in The New England Journal of … Continue reading Gene Therapy Nearly Eliminates Hemophilia B Bleeding Episodes, Trial Shows